Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Injection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16,230 result(s) found for: Injection. Displaying page 676 of 812.
    «« First « Previous 672  673  674  675  676  677  678  679  680  Next» Last»»
    EudraCT Number: 2022-000882-41 Sponsor Protocol Number: NN9535-4984 Start Date*: 2022-07-27
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of once-weekly semaglutide s.c. dose-response in patients with type 2 diabetes and overweight – a participant- and investigator-blinded and sponsor open-label study
    Medical condition: Diabetes Mellitus, Type 2 Overweight
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) GR (Trial now transitioned) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004529-22 Sponsor Protocol Number: D3465C00001 Start Date*: 2021-08-24
    Sponsor Name:AstraZeneca
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus
    Medical condition: Moderate-to-severe Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001773-24 Sponsor Protocol Number: GO40558 Start Date*: 2019-12-05
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED M...
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005573-12 Sponsor Protocol Number: LP0162-1335 Start Date*: 2022-10-05
    Sponsor Name:LEO Pharma A/S
    Full Title: A single (assessor) blinded, randomised, parallel-group, monotherapy trial to evaluate the pharmacokinetic and safety of tralokinumab in children (age 2 to <12 years) with moderate-to-severe atopic...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000938-34 Sponsor Protocol Number: MYTHS Start Date*: 2021-07-01
    Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA
    Full Title: Single blind randomized controlled trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant acute myocarditis
    Medical condition: Complicated/fulminant acute myocarditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10000932 Acute myocarditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023484-17 Sponsor Protocol Number: 2010-023484-17 Start Date*: 2011-06-11
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: LOCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01)
    Medical condition: High risk localized soft tissue sarcomas typical of the adult
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041299 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000952-36 Sponsor Protocol Number: CT-P39_3.1 Start Date*: 2021-02-05
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomati...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000267-72 Sponsor Protocol Number: D3252C00002 Start Date*: 2021-09-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps ...
    Medical condition: Patient with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) HU (Trial now transitioned) FR (Completed) PL (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002568-62 Sponsor Protocol Number: AVB-PGRN-001 Start Date*: 2023-03-13
    Sponsor Name:AviadoBio Ltd
    Full Title: A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal...
    Medical condition: Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003784-35 Sponsor Protocol Number: PS0015 Start Date*: 2018-08-27
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Pso...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-000137-17 Sponsor Protocol Number: BA3021-001 Start Date*: 2022-09-27
    Sponsor Name:BioAtla
    Full Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002048-42 Sponsor Protocol Number: MO29406 Start Date*: 2015-01-29
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-l...
    Medical condition: Solid Tumours (Future parent protocols may include other solid tumors that are not included in this section)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) IT (Trial now transitioned) FR (Ongoing) PL (Completed) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002933-12 Sponsor Protocol Number: DRM06-AD05 Start Date*: 2020-10-12
    Sponsor Name:Dermira, a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003406-31 Sponsor Protocol Number: CCMK389B12201 Start Date*: 2021-01-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject and investigator blinded, placebo-controlled multicenter study to assess the efficacy and safety of CMK389 in patients with moderate to severe atopic dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) FR (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002641-15 Sponsor Protocol Number: PBP-301 Start Date*: 2021-10-27
    Sponsor Name:Point BioPharma Inc.
    Full Title: SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
    Medical condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001221-27 Sponsor Protocol Number: R727-CL-1119 Start Date*: 2013-03-20
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins
    Medical condition: Patients with primary hypercholesterolemia and moderate, high or very high cardiovascular (CV) risk who are intolerant to statins
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) IT (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000620-34 Sponsor Protocol Number: Imatinib-MS Start Date*: 2018-04-24
    Sponsor Name:Department of Clinical Neuroscience, Karolinska Institutet
    Full Title: Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study
    Medical condition: Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where ther...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.0 10029205 - Nervous system disorders 10028247 Multiple sclerosis like syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004321-25 Sponsor Protocol Number: NordDutchCML009 Start Date*: 2013-04-03
    Sponsor Name:VU University Medical Center
    Full Title: A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af...
    Medical condition: Chronic myeloid leukemia in chronic phase and ≥ 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS).
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) SE (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002657-36 Sponsor Protocol Number: HMRI2012101/1 Start Date*: 2015-11-13
    Sponsor Name:University of Newcastle
    Full Title: Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
    Medical condition: Acute Ischaemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SE (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003643-29 Sponsor Protocol Number: VAC31518COV3009 Start Date*: 2020-11-10
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older E...
    Medical condition: Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) ES (Temporarily Halted) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 672  673  674  675  676  677  678  679  680  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 05:25:41 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA